| abstract |
One or more embodiments of the invention provide various novel formulations comprising olanzapine that are non-crystalline, which exhibit desired or improved stability, and/or possesses desired micromeritic properties and/or are otherwise improvements over known olanzapine formulations. The olanzapine-containing formulations may be administered to a user to treat psychotic conditions, especially schizophrenia and schizophenic conditions, and/or mania. |